Related references
Note: Only part of the references are listed.Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators
J. Dodt et al.
HAEMOPHILIA (2015)
Current laboratory practices in the diagnosis and management of haemophilia: a global assessment
S. Kitchen et al.
HAEMOPHILIA (2015)
Stability of coagulation proteins in lyophilized plasma
I. Jennings et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2015)
Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories
J. M. Sommer et al.
HAEMOPHILIA (2014)
Guidelines for the management of hemophilia
A. Srivastava et al.
HAEMOPHILIA (2013)
Practical and cost-effective measurement of B-domain deleted and full-length recombinant FVIII in the routine haemostasis laboratory
M. Cauchie et al.
HAEMOPHILIA (2013)
Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis
I. Mackie et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2013)
Recommendations on the potency labelling of factor VIII and factor IX concentrates
A. R. Hubbard et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Survey of laboratory tests used in the diagnosis and evaluation of haemophilia A
Keith Gomez et al.
THROMBOSIS AND HAEMOSTASIS (2013)
International comparative field study of N8 evaluating factor VIII assay performance
D. Viuff et al.
HAEMOPHILIA (2011)
Performance of recalibrated ReFacto® laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto® (B-domain deleted recombinant factor VIII)
C. Santoro et al.
HAEMOPHILIA (2009)
Laboratory performance in the World Federation of Hemophilia EQA programme, 2003-2008
I. Jennings et al.
HAEMOPHILIA (2009)
Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders - A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline - Approved by the British Committee for Standards in Haematology
D. Keeling et al.
HAEMOPHILIA (2008)
Emerging technologies and quality assurance: The United Kingdom National External Quality Assessment Scheme perspective
Ian Jennings et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2007)
Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays
J Ingerslev et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2004)
SSC/ISTH classification of hemophilia A: can hemophilia center laboratories achieve the new criteria?
FE Preston et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2004)
A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards
M Morfini et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2003)
A blinded in vitro study with Refacto® mock plasma samples:: similar FVIII results between the chromogenic assay and a one-stage assay when using a higher cephalin dilution
C Caron et al.
HAEMOPHILIA (2002)
A survey of one-stage and chromogenic potencies in therapeutic factor VIII concentrates
AR Hubbard et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Potency estimation of recombinant factor VIII: effect of assay method and standard
AR Hubbard et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Share Paper
